1. Introduction {#sec1}
===============

Aging is accompanied by a progressive decrease in fat-free mass, mostly due to the loss of muscle mass \[[@B1]\]. In addition, it has been reported that muscle atrophy results from chronic diseases such as diabetes, cancer, congestive heart failure, and chronic obstructive pulmonary disease, along with the disuse condition \[[@B2]\]. This inevitable decline of muscle mass followed by muscle weakness leads to both physical and physiological deteriorations that increase individual\'s frailty. Sarcopenia, an age-related decrease of muscle mass and strength, has been reported to be associated with physical disability, poor quality of life, high healthcare burden, and mortality \[[@B3], [@B4]\]. In this context, therapeutic strategies for the improvement of muscle function are important to preserve mobility in later years.

Loquat (*Eriobotrya japonica*) is a plant species belonging to the family Rosaceae and the loquat leaf extract (LLE) has been reported to contain ursolic acid (UA) \[[@B5], [@B6]\]. UA was found to reduce muscle atrophy and stimulate muscle hypertrophy in vivo study \[[@B7]\]. Moreover, another previous study revealed that the LLE supplements inhibited dexamethasone-induced reduction of muscle strength in Sprague-Dawley rats \[[@B8]\]. Accordingly, those results suggest the possibility of using LLE as a therapeutic agent for the prevention of skeletal muscle atrophy \[[@B7]\]. Based on evidence from these previous studies, we hypothesized that UA, which is the main component of LLE, has a positive effect on skeletal muscle mass, muscle strength, and muscle function in humans.

Therefore, we conducted a randomized, double-blinded, and placebo-controlled trial to investigate the effect of administration of the loquat leaf compound for 12 weeks on skeletal muscle mass, strength, and metabolic muscle markers in healthy adults; the safety of the compound was evaluated as well.

2. Material and Methods {#sec2}
=======================

2.1. Study Subjects and Ethics {#sec2.1}
------------------------------

The study was approved by the Institutional Review Board at Pusan National University Yangsan Hospital (02-2014-021), and written informed consents were obtained from all subjects prior to the study. Healthy adults were recruited through an official announcement at the tertiary hospital of Yangsan city. The eligibility criteria for enrollment were as follows: age between 19 and 65 years and body mass index (BMI) ranging from 18.5 to 30.0 kg/m^2^.

The exclusion criteria included abnormal liver or renal function (i.e., serum aminotransferase activity \> 60 IU/L and serum creatinine concentrations \> 1.2 mg/dL); diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL); history of fracture during the previous year; uncontrolled hypertension; history of serious cardiac disease such as angina or myocardial infarction; history of gastrectomy; history of medication for psychiatric disease; administration of oriental medicine including herbs within the past 4 weeks; and evidence of relatively high skeletal mass (more than 110% of the standard lean body mass as measured using the body composition analyzer InBody 720) \[[@B9]\].

2.2. Study Design {#sec2.2}
-----------------

This study was a randomized, double-blinded, and placebo-controlled trial. A simple randomization technique based on number tables was used to assign each participant to either the intervention or the control group. The participants were assigned randomization numbers sequentially and these randomization codes were held by the company that manufactured the LLE and the dummy placebo. The measurements were conducted by people with no access to the randomization process of the participants.

After the baseline assessment, subjects were randomly allocated to either the LLE- or the placebo-supplemented group. Each subject was instructed to visit the clinic after 4 (±3 days) and 12 (±7 days) weeks from the beginning of the treatment. On each visit, evaluation of muscle mass, anthropometric measurement of body composition, physical performance test, and blood sampling were performed for every participant.

2.3. Treatments {#sec2.3}
---------------

The LLE, obtained from dried loquat leaf, contained 102 mg/g of UA as the major component, and each capsule (Korea Pharmacy Corporation, CHO-A PHARM Co., Ltd.) contained 250 mg of LLE. 500 mg (UA 50.94 mg) per day of LLE was administered to the subjects in the intervention group 30 minutes after breakfast and dinner for 12 weeks. The same quantity of placebo was administered to the subjects in the control group twice a day for 12 weeks. The placebo had an identical appearance and taste as the LLE capsule.

2.4. Muscle Strength {#sec2.4}
--------------------

A Biodex® System 3 Pro isokinetic dynamometer (Biodex, Inc., Shirley, NY, USA) was used to measure the peak torque (TQ) at 60°/s knee extension movements and the peak TQ/body weight was calculated at 60°/s knee extension. The handgrip strength was measured using a hydraulic hand dynamometer (Jamar, Jackson, MI). Three consecutive measurements of handgrip strength of both hands were recorded with subjects sitting in an upward position and their arms at a 90° angle position, and the maximum strength effort was determined.

2.5. Body Composition {#sec2.5}
---------------------

BMI was calculated as weight (kg) divided by square of height (m^2^). A mercury sphygmomanometer was used to measure the blood pressure of each subject in the sitting position after a 10 min resting period. Two readings, each for systolic and diastolic blood pressure, were recorded at 3 min intervals, and the average of each measurement was used for analyses. A well-trained radiological technologist measured the body composition using a dual-energy X-ray absorptiometry (DXA). We calculated the appendicular skeletal muscle (ASM)/height^2^ and ASM/weight as skeletal muscle mass indices.

2.6. Physical Performance {#sec2.6}
-------------------------

The subject\'s physical performance was assessed using the short physical performance battery (SPPB), which consists of 3 components: balance, 4 m gait speed, and chair-rise ability \[[@B10]\]. A well-trained study nurse performed all examinations.

2.7. Blood Sampling {#sec2.7}
-------------------

Blood samples after a 12 h overnight fast were collected at baseline and 4 and 12 weeks after the randomization for general blood testing, biochemical testing, and lipid testing to evaluate metabolic risk factors and monitor on potential adverse effects of LLE. The serum creatinine and blood pyruvate levels were measured by Jaffe\'s kinetic alkaline picrate method and the enzymatic method, respectively. Lactate concentrations and serum electrolytes levels were measured using an ion-selective electrode, while serum creatinine kinase (CK) concentration was measured using the kinetic ultraviolet method. Liver enzyme and total cholesterol levels were measured with Toshiba TBA200FR (Toshiba Co. Ltd., Tokyo, Japan) using an enzymatic colorimetric method, and low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol were measured with Toshiba TBA200FR directly. Triglycerides were measured using lipase, glycerol kinase (GK), glycerol-3-phosphate oxidase (GPO), and peroxidase (POD) with a glycerol blank. Fasting blood sugar was measured using a glucose oxidase test method (LX-20, Beckman Coulter, Fullerton, CA, USA), and the serum insulin concentration was measured using Coat-A-Count® Insulin with solid-phase 125I radioimmunoassay.

2.8. Nutrition and Exercise Assessments {#sec2.8}
---------------------------------------

The diet of each subject was monitored by a semiquantitative food frequency questionnaire at baseline and after 12 weeks. Participants were asked to report the frequency of consumption of 53 food items contained in the semiquantitative food frequency questionnaire over a period of 2 weeks prior to administration \[[@B11]\]. The total intake of energy and essential nutrients including protein, fat, and carbohydrate of participants was calculated using the questionnaire. Physical activity was assessed using the International Physical Activity Questionnaire (IPAQ) at baseline and after 12 weeks \[[@B12]\]. The physical activity levels were expressed as metabolic equivalent- (MET-) minute. METs are multiples of the resting metabolic rates. An MET-minute is computed by multiplying the MET score of an activity by its duration (in minutes). MET-minute scores are equivalent to kilocalories for a person weighing 60 kg.

2.9. Statistical Analysis {#sec2.9}
-------------------------

The primary outcome measure was 60°/s knee extension peak TQ at an angular velocity of 60°/s. The secondary outcome measures included peak TQ/body weight; handgrip strength measurement; and lean mass measured by DXA, SPPB, and other laboratory markers related to the muscle, such as pyruvate, lactate, and creatinine. The average knee extension peak TQ at an angular velocity of 60°/s was set at 67 Nm \[[@B13]\], and the difference in pre- and posttreatment changes in knee peak TQ between the placebo and the control groups was set at 5% with reference to 0--11% from a previous study \[[@B14]\], while the average difference between the placebo and the control groups to be detected was set at 5% of 67 Nm and 3.35 Nm. With a standard deviation (SD) of 3.9 Nm, based on a previous study, a minimum of 21 subjects per group would be required to detect a difference in knee peak TQ (power = 80% and alpha error = 0.05) \[[@B15]\]. Using this calculation, we assumed a 20% dropout rate and selected 27 subjects per group for the present study. When the test data were unavailable, the last recorded data were used in the analysis (called the last observation carried forward). Efficacy analyses were based on the intent-to-treat population of subjects who received at least one dose of the prescribed LLE or placebo. The Shapiro-Wilk test was adopted to test the normality of the variables. Results are expressed as mean ± SD because the variables were all normally distributed. The between-group comparisons for baseline characteristics and the changes after 4 and 12 weeks were performed using a two-sample*t*-test for continuous variables as appropriate or the chi-square test in case of categorical variables. The within-group comparisons were done with a paired*t*-test. *P* value less than 0.05 was considered statistically significant. The SAS ver. 9.3 was used for all statistical analyses.

3. Results {#sec3}
==========

3.1. Subject {#sec3.1}
------------

Sixty-five subjects were enrolled; of which, 54 subjects went through the randomization. Twenty-four subjects (88.9%) in the LLE group and 22 subjects (81.5%) in the control group completed the visits. The average compliance rates were 93.2% in the LLE group and 92.5% in the control group; these values did not differ between the groups. The baseline characteristics of the study subjects are presented in [Table 1](#tab1){ref-type="table"}, and no significant differences were observed between the two groups, except in the gender ratio (*P* = 0.004). The number of men in the control group was four times higher than the number in the LLE group, even though they were assigned randomly. Caloric intake, intake of essential nutrients, and physical activity recorded in MET-minute remained unchanged within the group and between the groups throughout the entire 12 weeks.

3.2. Muscle Strength {#sec3.2}
--------------------

At baseline, the muscle strength parameters did not differ between the two groups (all *P* \> 0.05) ([Table 2](#tab2){ref-type="table"}). Throughout the 12 weeks, no significant differences in muscle strength were observed between the two groups (all *P* \> 0.05). Statistically, the right-handgrip strength significantly increased in the two groups at 12 weeks (*P* \< 0.001, *P* \< 0.05) ([Table 2](#tab2){ref-type="table"}). However, no significant differences were reported in the handgrip strength between the two groups over time ([Table 2](#tab2){ref-type="table"}).

Additionally, we performed the analysis based on gender because the sex proportion differed between the two groups (control group: 8 male subjects \[29.6%\]; LLE group: 2 male subjects \[7.4%\]). Statistically significant differences were observed in the right-handgrip strength during the 12 weeks between the LLE group and the control group (Δ right-handgrip strength, 2.3 ± 2.96 versus 0.62 ± 2.28, *P* = 0.047). However, changes during 4 weeks were similar between the two groups (Δ right-handgrip strength, 0.87 ± 2.58 versus 0.26 ± 2.39, *P* = 0.431) ([Figure 1](#fig1){ref-type="fig"}).

3.3. Muscle Mass {#sec3.3}
----------------

ASM/height^2^ and ASM/weight × 100 showed that the muscle mass had not changed in the two groups at 12 weeks (*P* = 0.924 and *P* = 0.976) ([Table 3](#tab3){ref-type="table"}). After 4 and 12 weeks, the total fat percent decreased in both the groups; however, no significant differences were observed in the two groups (*P* = 0.561 and *P* = 0.125).

3.4. Physical Performance {#sec3.4}
-------------------------

The balance test score SPPB did not change in each group at 12 weeks (*P* = 0.327 and not applicable). However, 4 m gait speed and chair-rising time significantly improved in both groups at 12 weeks (*P* = 0.017 and *P* = 0.033; *P* \< 0.001 and *P* \< 0.001), with no other differences between the two groups (*P* = 0.699 and *P* = 0.672) ([Table 3](#tab3){ref-type="table"}).

3.5. Blood Measurements {#sec3.5}
-----------------------

No significant differences were observed in the laboratory test results for pyruvate, lactate, electrolyte, glucose, and CK levels and the lipid profile, as well as liver and renal function between the two groups ([Table 4](#tab4){ref-type="table"}).

3.6. Safety {#sec3.6}
-----------

One of participants in the control group complained of skin rash and decided to drop out. Otherwise, no other adverse effects were observed in the LLE group.

4. Discussion {#sec4}
=============

To our knowledge, the present study is the first randomized, double-blind, and placebo-controlled trial to investigate the efficacy and the safety of LLE supplementation for improving muscle strength, muscle mass, and muscle function. This study also showed that an LLE supplementation dose of 500 mg/day over 12 weeks had no favorable effects on muscle mass and function in healthy adults. However, the right-handgrip strength statistically improved in LLE-supplemented female subjects compared to that in the placebo group female subjects throughout the 12-week period.

Previous studies have suggested therapeutic options for the improvement of muscle mass and function mainly based on a combination of protein supplementation and exercise \[[@B16]--[@B18]\]. In a previous study, dietary protein supplementation caused improvements in the physical performance of 65 frail elderly subjects but failed to increase the skeletal muscle mass \[[@B16]\]. In contrast, another study on sarcopenic female patients demonstrated that exercise and simultaneous amino acid supplementation (3 g leucine-rich essential amino acid mixture administered twice a day) enhanced muscle strength and muscle mass variables and physical performances, such as walking speed \[[@B17]\]. In addition, a recent study including 44 healthy young men showed that 3 months of resistance-type exercise training increased skeletal muscle mass, strength, and muscle fiber size. Along with exercise training, a group supplemented daily with dietary proteins (27.5 g) before sleep showed a more demonstrated increase in muscle mass and strength when compared with the group undergoing exercise training alone \[[@B18]\]. Consistent with those results, the Society for Sarcopenia, Cachexia, and Wasting Disease recommended appropriate protein and energy intake with exercise for the prevention of sarcopenia \[[@B19]\].

Several studies suggest new therapeutic strategies for the prevention of aging-associated decline in muscle mass and function \[[@B20], [@B21]\]. Fish oil-derived n-3 PUFA therapy for 6 months showed significant beneficial effects on thigh volume, handgrip strength, and upper- and lower-body 1-RM muscle strength when compared with the placebo group \[[@B20]\]. In another study, the use of high whey protein-, leucine-, and vitamin D-enriched supplements preserved appendicular muscle mass in obese older adults on a hypocaloric diet and resistance exercise program when compared with that of an isocaloric control group \[[@B21]\]. However, treatments for the prevention and improvement of sarcopenia are still not sufficient to meet the demands.

In oriental medicine, LLE, a common ingredient in teas and food, and UA, a major active component of loquat leaves, are used. A study based on microarray analysis reported that UA reduced skeletal muscle atrophy under two distinct atrophy-inducing stress conditions (fasting and muscle denervation). This particular in vivo study also demonstrated that long-term treatment with UA increased Akt phosphorylation and mRNA expression of insulin-like growth factor-1 \[[@B7]\]. Another study showed that UA directly promoted protein accretion in cultured myotubes but did not modulate myoblast proliferation \[[@B22]\]. However, the risks associated with the use of UA also have to be considered because of unfavorable side effects at high dose, including compromised viability of both myoblasts and myotubes \[[@B8]\] and toxic myopathy \[[@B23]\]. In this context, we performed a human study to evaluate the effect and safety of LLE in improving skeletal muscle mass, strength, and metabolic muscle markers for medical usage.

In the present study, unfortunately, we were unable to show the positive effects of LLE on muscle strength, muscle mass, and muscle function in healthy adults. The negative results could be explained, in part, by the use of insufficient dosage of the active component. Subjects in the intervention group daily received 500 mg of LLE supplement, which contained 50.94 mg of UA. In our preliminary study, we confirmed that 50 mg/kg/day of LLE supplement over a period of 5 weeks increased the muscle mass in rats. Therefore, our planned treatment dose was 1000 mg/day at the beginning of the study. However, we had to decrease the dose to 500 mg/day because a long-term human study using LLE had not been conducted in the past. Secondly, this study excluded exercise training to evaluate primarily the effect of LLE during the study. In a prior study, community-dwelling elderly sarcopenic women were randomly assigned to one of the four groups: exercise and amino acid supplementation (exercise + AAS), exercise, AAS, or health education \[[@B17]\]. The knee extension strength improved significantly only in the exercise + AAS group, and no improvement was seen in the other groups. Lastly, more than 12 weeks may be required to notice positive results. According to the subgroup analysis of our data, the right-handgrip strength of the LLE group significantly increased only after 12 weeks but showed no significant change after 4 weeks.

Our study had some limitations including lack of histological confirmation to determine the action mechanism of LLE in the muscle and inability to measure UA levels in blood. Moreover, despite the randomization process, the female sex ratio was quite high in all the groups. Because testosterone and androgen are known to affect muscle growth and muscle mass, the efficacy of LLE may vary depending on the gender. However, the prospective design of this study compensates in part for these limitations. We stratified the analysis into subjects aged \<45 and those aged 45+ owing to the relatively wide age range of study participants; however, the results of subgroup analysis were not different. Our study participants cannot represent entire population because we excluded people with relatively high skeletal muscle mass. Other limitations include insufficient LLE dosage and abstinence from additional exercising for the study\'s duration. In addition, there was a concern regarding the validity of the physical performance evaluation tool. The SPPB system was adopted for the evaluation of subjects\' physical performance score, even though the system was originally intended to be used only in elderly people.

In conclusion, LLE supplementation did not improve muscle strength, muscle mass, and muscle function in healthy adults. However, the right-handgrip strength of female subjects in the LLE group showed significant improvement when compared with that of the female subjects in the placebo group. Further well-designed researches are needed to determine the appropriate dose ranges and duration of LLE supplementation and to increase the usefulness of our first-stage study outcome in various clinical settings.

This work was supported by the R&D program of MOTIE/KEIT (10040391, Development of Functional Food Materials and Device for Prevention of Aging-Associated Muscle Function Decrease).

Competing Interests
===================

The authors declare no competing interests regarding the publication of this paper.
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###### 

Baseline characteristics of the study group.

  -------------------------------------------------------------------------------
                                   LLE\             Placebo\         *P* ^(1)^
                                   (*n* = 27)       (*n* = 27)       
  -------------------------------- ---------------- ---------------- ------------
  Age, years                       40.0 ± 11.3      38.2 ± 12.0      0.586

  Males, %                         2 (7.4)          8 (29.6)         **0.004**

  Systolic blood pressure, mmHg    113.7 ± 10.7     115.8 ± 12.6     0.509

  Diastolic blood pressure, mmHg   73.3 ± 6.8       72.2 ± 11.7      0.671

  Non-smoker, %                    27 (100)         24 (88.9)        0.721^(2)^

  Body mass index, kg/m^2^         22.2 ± 2.4       22.8 ± 2.6       0.410

  Activity, METs/week              25.8 ± 24.6      27.3 ± 33.5      0.852

  Energy intake, Kcal/day          1709.1 ± 467.2   1816.8 ± 313.9   0.326

  Protein intake, g/day            68.8 ± 22.4      70.0 ± 17.2      0.827

  Fat intake, g/day                44.9 ± 15.4      45.5 ± 16.0      0.887

  Carbohydrate intake, g/day       257.5 ± 70.9     281.8 ± 55.4     0.166
  -------------------------------------------------------------------------------

LLE: loquat leaf extract; MET: metabolic equivalent.

One MET is approximately equal to 1 kcal/min for a person weighing 60 kg.

Data are expressed as mean ± SD or in frequency (percent).

^(1)^Statistical differences are based on two-sample *t*-test or chi-square test.

^(2)^Fisher\'s exact test.

###### 

Comparison of the muscle strength of the two groups.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                         Group          Week 0^(1)^    Week 4^(1)^    Δ4-0 weeks   *P* ^(2)^      Week 12^(1)^   Δ12-0 weeks   *P* ^(2)^
  ------------------------------------------------- -------------- -------------- -------------- ------------ -------------- -------------- ------------- -------------
  60°/s knee extension peak TQ (Rt), Nm             LLE\           87.8 ± 38.4    89.8 ± 34.3    2.0 ± 16.8   0.543          90.2 ± 33.6    2.4 ± 18.6    0.513
                                                    (*n* = 27)                                                                                            

  Placebo\                                          101.2 ± 39.5   101.0 ± 33.4   −0.2 ± 20.9    0.969        109.9 ± 45.8   8.7 ± 23.9     0.070         
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.678                       *P* ^(3)^      0.285                        

                                                                                                                                                          

  60°/s knee extension peak TQ (Lt), Nm             LLE\           86.9 ± 31.3    91.5 ± 36.0    4.6 ± 17.5   0.182          92.0 ± 34.5    5.1 ± 15.4    0.094
                                                    (*n* = 27)                                                                                            

  Placebo\                                          96.9 ± 32.6    104.7 ± 42.0   7.8 ± 19.8     0.051        109.1 ± 41.0   12.2 ± 19.2    **0.003**     
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.534                       *P* ^(3)^      0.143                        

                                                                                                                                                          

  60°/s knee extension peak TQ/weight (Rt), Nm/kg   LLE\           148.8 ± 52.0   153.1 ± 45.7   4.3 ± 28.1   0.435          153.8 ± 45.0   5.1 ± 31.9    0.417
                                                    (*n* = 27)                                                                                            

  Placebo\                                          161.4 ± 48.4   163.1 ± 44.0   1.7 ± 32.1     0.786        174.6 ± 55.0   13.2 ± 35.2    0.062         
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.754                       *P* ^(3)^      0.376                        

                                                                                                                                                          

  60°/s knee extension peak TQ/weight (Lt), Nm/kg   LLE\           148.9 ± 45.4   156.0 ± 49.1   7.1 ± 27.9   0.196          157.0 ± 46.9   8.1 ± 25.4    0.111
                                                    (*n* = 27)                                                                                            

  Placebo\                                          155.9 ± 42.0   166.8 ± 50.0   11.0 ± 28.2    0.054        173.4 ± 47.2   17.5 ± 27.9    **0.003**     
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.617                       *P* ^(3)^      0.201                        

                                                                                                                                                          

  Handgrip (L), kg                                  LLE\           26.8 ± 4.9     27.7 ± 5.9     0.9 ± 2.8    0.100          28.0 ± 6.7     1.2 ± 4.1     0.151
                                                    (*n* = 27)                                                                                            

  Placebo\                                          30.0 ± 8.8     30.3 ± 9.5     0.3 ± 3.3      0.611        31.3 ± 9.8     1.3 ± 3.7      0.083         
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.485                       *P* ^(3)^      0.908                        

                                                                                                                                                          

  Handgrip (R), kg                                  LLE\           28.6 ± 6.1     29.4 ± 6.4     0.8 ± 2.6    0.138          31.2 ± 7.2     2.6 ± 3.1     **\<0.001**
                                                    (*n* = 27)                                                                                            

  Placebo\                                          31.1 ± 9.3     31.8 ± 10.1    0.7 ± 4.9      0.436        33.3 ± 11.1    2.2 ± 5.0      **0.031**     
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.978                       *P* ^(3)^      0.748                        

                                                                                                                                                          

  Handgrip (mean), kg                               LLE\           27.7 ± 5.4     28.6 ± 5.9     0.9 ± 2.1    **0.045**      29.6 ± 6.7     1.9 ± 3.2     **0.005**
                                                    (*n* = 27)                                                                                            

  Placebo\                                          30.6 ± 8.9     31.1 ± 9.7     0.5 ± 3.8      0.471        32.3 ± 10.4    1.7 ± 4.0      **0.032**     
  (*n* = 27)                                                                                                                                              

                                                                   *P* ^(3)^      0.714                       *P* ^(3)^      0.901                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

LLE: loquat leaf extract; TQ: torque; NA: not applicable.

Data are expressed as mean ± SD.

^(1)^ *P* \> 0.05 by two-sample test.

^(2)^Paired *t*-test for within-group.

^(3)^Two-sample test between groups for comparison of the difference from baseline.

###### 

Comparison of the muscle mass and muscle function between the two groups.

  Variables                     Group            Week 0^(1)^   Week 4^(1)^    Δ4-0 weeks     *P* ^(2)^     Week 12^(1)^   Δ12-0 weeks    *P* ^(2)^
  ----------------------------- ---------------- ------------- -------------- -------------- ------------- -------------- -------------- -------------
  ASM/height^2^, kg/m^2^        LLE (*n* = 27)   5.4 ± 0.7     5.6 ± 0.7      0.12 ± 0.21    **0.007**     5.5 ± 0.7      0.02 ± 0.21    0.662
  Placebo (*n* = 27)            5.9 ± 1.1        6.0 ± 1.2     0.13 ± 0.33    **0.047**      5.9 ± 1.1     0.02 ± 0.21    0.567          
                                                 *P* ^(3)^     0.841                         *P* ^(3)^     0.924                         
                                                                                                                                         
  ASM/weight × 100, %           LLE (*n* = 27)   24.7 ± 3.0    25.1 ± 2.9     0.42 ± 0.91    **0.025**     24.8 ± 3.1     0.06 ± 0.92    0.723
  Placebo (*n* = 27)            25.9 ± 3.8       26.5 ± 4.3    0.57 ± 1.5     0.058          26.0 ± 3.9    0.07 ± 0.91    0.691          
                                                 *P* ^(3)^     0.651                         *P* ^(3)^     0.976                         
                                                                                                                                         
  Trunk fat percent, %          LLE (*n* = 27)   32.5 ± 5.9    31.1 ± 5.1     −1.41 ± 2.49   **0.007**     31.3 ± 5.4     −1.24 ± 1.62   **\<0.001**
  Placebo (*n* = 27)            30.7 ± 5.4       29.7 ± 6.0    −1.03 ± 2.31   **0.028**      30.2 ± 5.2    −0.54 ± 1.7    0.112          
                                                 *P* ^(3)^     0.561                         *P* ^(3)^     0.125                         
                                                                                                                                         
  Total fat percent, %          LLE (*n* = 27)   34.1 ± 5.0    33.0 ± 4.8     −1.03 ± 1.69   **0.004**     33.2 ± 4.8     −0.86 ± 1.11   **\<0.001**
  Placebo (*n* = 27)            32.1 ± 6.0       31.0 ± 6.5    −1.09 ± 1.78   **0.004**      31.3 ± 5.9    −0.74 ± 1.29   **0.006**      
                                                 *P* ^(3)^     0.907                         *P* ^(3)^     0.736                         
                                                                                                                                         
  SPPB (balance), score         LLE (*n* = 27)   4.0 ± 0.2     4.0 ± 0        0.04 ± 0.19    0.327         4.0 ± 0        0.04 ± 0.19    0.327
  Placebo (*n* = 27)            4.0 ± 0          4.0 ± 0.2     −0.04 ± 0.19   0.327          4.0 ± 0       0 ± 0          NA             
                                                 *P* ^(3)^     0.163                         *P* ^(3)^     0.322                         
                                                                                                                                         
  SPPB (4 m gait speed), s      LLE (*n* = 27)   2.3 ± 0.3     2.2 ± 0.3      −0.07 ± 0.29   0.197         2.1 ± 0.3      −0.14 ± 0.29   **0.017**
  Placebo (*n* = 27)            2.2 ± 0.3        2.2 ± 0.3     −0.04 ± 0.31   0.537          2.1 ± 0.3     −0.11 ± 0.27   **0.033**      
                                                 *P* ^(3)^     0.651                         *P* ^(3)^     0.699                         
                                                                                                                                         
  SPPB (chair-rising time), s   LLE (*n* = 27)   10.4 ± 2.6    8.6 ± 1.9      −1.84 ± 2.49   **\<0.001**   7.9 ± 1.7      −2.51 ± 2.23   **\<0.001**
  Placebo (*n* = 27)            10.5 ± 3.2       8.3 ± 2.2     −2.21 ± 2.03   **\<0.001**    7.7 ± 2.3     −2.76 ± 2.05   **\<0.001**    
                                                 *P* ^(3)^     0.548                         *P* ^(3)^     0.672                         

ASM: appendicular skeletal muscle; LLE: loquat leaf extract; SPPB: short physical performance battery; NA: not applicable.

Data are expressed as mean ± SD.

^(1)^ *P* \> 0.05 by two-sample test.

^(2)^Paired *t*-test for within-group.

^(3)^Two-sample test between groups for comparison of the difference from baseline.

###### 

Comparison of the metabolic parameters between the two groups.

  Variables      LLE group (*n* = 27)   Placebo group (*n* = 27)   *P* ^(2)^                                                                                
  -------------- ---------------------- -------------------------- -------------- ------------- --------------- -------------- -------------- ------------- -------
  Pyruvate       0.85 ± 0.41            0.75 ± 0.49                −0.11 ± 0.53   0.307         0.87 ± 0.4      0.85 ± 0.31    −0.02 ± 0.38   0.773         0.499
  Lactate        1.32 ± 0.89            1.02 ± 0.54                −0.3 ± 0.86    0.085         1.41 ± 0.93     1.31 ± 0.77    −0.11 ± 0.84   0.514         0.419
  Creatinine     0.71 ± 0.12            0.66 ± 0.14                −0.06 ± 0.11   **0.017**     0.74 ± 0.18     0.69 ± 0.17    −0.06 ± 0.11   **0.014**     0.990
  AST            23.2 ± 4.9             19.8 ± 4.4                 −3.4 ± 4.3     **\<0.001**   23.6 ± 4.4      20.6 ± 4.0     −3.1 ± 3.5     **\<0.001**   0.783
  ALT            13.3 ± 4.0             12.5 ± 4.5                 −0.7 ± 3.0     0.210         15.5 ± 6.5      13.8 ± 5.1     −1.7 ± 5.3     0.116         0.435
  GGT            15.4 ± 7.5             14.3 ± 6.7                 −1.2 ± 3.2     0.061         20.3 ± 13.1     18.8 ± 15.2    −1.4 ± 5.0     0.149         0.822
  Glucose        89 ± 6.5               91.8 ± 10.0                2.8 ± 8.9      0.113         91.7 ± 9.4      95.0 ± 10.5    3.3 ± 8.1      0.044         0.836
  Insulin        4.4 ± 1.5              4.9 ± 2.3                  0.5 ± 1.8      0.166         5.4 ± 2.6       5.7 ± 3.3      0.4 ± 3.2      0.561         0.872
  CK             88.2 ± 42.4            77.4 ± 29.6                −10.8 ± 40.0   0.173         125.1 ± 195.2   116 ± 137.6    −9.1 ± 68.1    0.493         0.913
  Na             140.1 ± 1.5            139.0 ± 2.2                −1.1 ± 2.6     **0.045**     140.2 ± 1.6     139.4 ± 2.0    −0.8 ± 1.9     **0.038**     0.635
  K              4.3 ± 0.3              4.2 ± 0.3                  −0.1 ± 0.4     0.201         4.4 ± 0.3       4.3 ± 0.2      −0.1 ± 0.3     0.051         0.862
  Cl             104.6 ± 1.8            103.6 ± 1.6                −0.9 ± 2.0     **0.022**     104.6 ± 1.8     104.3 ± 2.3    −0.4 ± 1.7     0.272         0.275
  HDL            61.3 ± 12.5            60.3 ± 12.6                −1 ± 8.8       0.558         58.9 ± 13.1     58.4 ± 15.0    −0.5 ± 9.7     0.784         0.849
  LDL            101.1 ± 25.5           144.3 ± 119.2              43.1 ± 122.3   0.084         100.9 ± 23.1    112.9 ± 28.7   12 ± 21.4      **0.007**     0.199
  Triglyceride   80.7 ± 50.8            78.6 ± 35.3                −2.07 ± 31.7   0.736         85.1 ± 46.0     77.7 ± 36.4    −7.4 ± 30.1    0.210         0.526

LLE: loquat leaf extract; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: *γ*-glutamyl transferase; CK: creatinine kinase; HDL: high-density lipoprotein; LDL: low-density lipoprotein.

Data are expressed as mean ± SD.

^(1)^Paired *t*-test for within-group.

^(2)^Two-sample test between groups for comparison of the difference from baseline.

[^1]: Academic Editor: Ken Yasukawa
